SYNLOGIC 8-K Details Operations, Exit Costs, Officer Comp Changes

TL;DR

**SYNLOGIC just dropped an 8-K hinting at big operational changes and officer compensation shifts.**

AI Summary

SYNLOGIC, INC. filed an 8-K on February 12, 2024, reporting on various events including results of operations, financial condition, costs associated with exit or disposal activities, and changes in officers' compensatory arrangements. This filing indicates potential strategic shifts or restructuring within the company, which could impact its financial performance and future prospects. Investors should pay close attention to the details of these changes as they may signal a re-evaluation of the company's operational strategy and financial health, potentially affecting stock valuation.

Why It Matters

This filing signals potential operational restructuring and financial adjustments at SYNLOGIC, INC., which could significantly influence its future profitability and stock performance.

Risk Assessment

Risk Level: medium — The filing mentions 'Cost Associated with Exit or Disposal Activities' and 'Compensatory Arrangements of Certain Officers,' which could indicate significant strategic shifts or financial pressures, introducing uncertainty.

Analyst Insight

A smart investor would closely monitor SYNLOGIC's upcoming financial reports and press releases for specific details on the 'exit or disposal activities' and 'compensatory arrangements' to understand the full impact on the company's strategic direction and financial health.

Key Players & Entities

• SYNLOGIC, INC. (company) — the registrant filing the 8-K
• February 12, 2024 (date) — date of earliest event reported and filing date
• 001-37566 (other) — Commission File Number for SYNLOGIC, INC.
• 301 Binney St. Suite 402, Cambridge, Massachusetts, 02142 (other) — Address of Principal Executive Offices for SYNLOGIC, INC.
• (617) 401-9975 (other) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SYBX The NASDAQ Capital M
• $47.7 million — tments balance at December 31, 2023 was $47.7 million. The full text of the press release is
• $6 million — imates that it will incur approximately $6 million of costs in connection with the reducti

Filing Documents

• sybx-20240212.htm (8-K) — 49KB
• sybx-ex99_1.htm (EX-99.1) — 18KB
• img56602281_0.jpg (GRAPHIC) — 24KB
• 0000950170-24-013803.txt ( ) — 229KB
• sybx-20240212.xsd (EX-101.SCH) — 32KB
• sybx-20240212_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 8, 2024, Synlogic, Inc. (the "Company") issued a press release providing the following financial information. The Company's cash, cash equivalents and short-term investments balance at December 31, 2023 was $47.7 million. The full text of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference. The cash, cash equivalents and short-term investments balance information above is based on preliminary unaudited information and management estimates for the year ended December 31, 2023, is not a comprehensive statement of the Company's financial results as of and for the fiscal year ended December 31, 2023, and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, this preliminary estimate. The information contained in this item is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On February 8, 2024, the Company announced that it is implementing a reduction in workforce by approximately 90%. The decision was based on cost-reduction initiatives intended to reduce the Company's ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options. The Company expects to complete substantially all of the reduction in workforce by the end of the fiscal quarter ending March 31, 2024. The Company estimates that it will incur approximately $6 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The charges the Company expects to incur in connection with this reduction in workforce are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the reduction in workforce, the Company and Aoife Brennan, M.B. Ch.B., the Company's President and Chief Executive Officer, agreed on February 8, 2024 that Dr. Brennan's employment with the Company will terminate effective as of March 9, 2024. The Company expects to enter into a consulting arrangement with Dr. Brennan in connection with her separation. On February 8, 2024, Dr. Brennan also resigned from the Company's Board of Directors, effective March 9, 2024. Dr. Brennan's resignation was not as a result of any disagreement between Dr. Brennan and the Company on any matter relating to the Company's operations, policies or practices.

01. Other Events

Item 8.01. Other Events. On February 8, 2024, the Company issued a press release announcing the discontinuation of Synpheny-3, the ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria. As a result, the Company's management and its Board of Directors have made the decision to cease operations, evaluate strategic options for the Company and reduce its workforce by approximately 90%. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: February 12, 2024 Synlogic, Inc. By: /s/ Aoife Brennan Name: Title: Aoife Brennan President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR